Bristol Shrugs Off Lirilumab Phase II Mono Trial Failure; Eyes Combo Trials
Bristol says its combination development program for lirilumab - licensed from Innate Pharma in 2011 – remains unaffected by news the anti-KIR checkpoint inhibitor failed in a Phase II trial in elderly patients with acute myeloid leukemia as a maintenance monotherapy.
You may also be interested in...
Phase I candidate already tested in rheumatoid arthritis could be used to optimize the activity of T cells and NK cells in the tumor microenvironment, either in combination with checkpoint inhibitors or as a solo agent.
Merck claims first Phase III survival data in bladder cancer for Keytruda, while Bristol shows potential for immunotherapy combinations in bladder and head and neck cancers at the annual SITC meeting.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.